Furthermore, overexpression of IR-A in cancer cells confers resistance to monoclonal antibody therapy, such as trastuzumab (an anti-IGF1-R antibody), suggesting that IR expression can serve as a predictive molecular marker for resistance to tumor-targeted therapies [85]. Here, IGF1R is linked to cancer.